Chest to distribute Aerocrine airway inflammation
detector in Japan
20 February 2008
Swedish airway products company Aerocrine AB (STO:AERO) has entered into
a distribution agreement with Chest MI Inc to market and sell Aerocrine's
Niox Mino in Japan.
Niox Mino is a handheld device that in a couple of minutes gauges the
inflammation in the airways, the underlying cause of asthma.
Treatment of asthma focuses primarily on keeping the inflammation under
control, which leads to fewer symptoms and less acute asthma exacerbations.
Eight million people suffers from asthma in Japan and the disease causes
around 3,000 deaths yearly, primarily due to inferior disease control.
Chest manufactures and sells products to measure lung function and oxygen
delivery systems for home use. It has a 50% share of the Japanese market and
over 10 local sales offices
"Chest is an ideal partner for marketing and sales of our product in
Japan," says Paul de Potocki, CEO of Aerocrine. "The company has established
relations and years of experience from selling medical devices to our prime
target groups. Chest has also shown an impressive knowledge and enthusiasm
for our product and method of inflammatory control."
Aerocrine is headquartered in Sweden and has subsidiaries in the US,
Germany and the UK.